Long-term visit-to-visit variability in low-density lipoprotein cholesterol is associated with poor cardiovascular and kidney outcomes in patients with primary nephrotic syndrome

[1]  B. Rovin,et al.  KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.

[2]  T. A. Jacobson,et al.  Dyslipidemia in Patients with Kidney Disease. , 2021, Cardiology clinics.

[3]  Tingting Wang,et al.  Short‐Term Systolic Blood Pressure Variability and Kidney Disease Progression in Patients With Chronic Kidney Disease: Results From C‐STRIDE , 2020, Journal of the American Heart Association.

[4]  Qiang He,et al.  The association between dyslipidemia and the incidence of chronic kidney disease in the general Zhejiang population: a retrospective study , 2020, BMC Nephrology.

[5]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[6]  S. Bangalore,et al.  Risk Factor Variability and Cardiovascular Outcome: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[7]  Kyungdo Han,et al.  Associations of Variability in Blood Pressure, Glucose and Cholesterol Concentrations, and Body Mass Index With Mortality and Cardiovascular Outcomes in the General Population , 2018, Circulation.

[8]  C. Zoccali,et al.  Lipid management in patients with chronic kidney disease , 2018, Nature Reviews Nephrology.

[9]  F. Sánchez‐Madrid,et al.  Variability in atherogenic lipoproteins and coronary artery disease progression , 2018, European heart journal.

[10]  S. le Cessie,et al.  Visit-to-visit lipid variability: Clinical significance, effects of lipid-lowering treatment, and (pharmaco) genetics. , 2018, Journal of clinical lipidology.

[11]  Hun‐Sung Kim,et al.  Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study , 2017, European heart journal.

[12]  Yu-Hsuan Lin,et al.  Greater low-density lipoprotein cholesterol variability is associated with increased progression to dialysis in patients with chronic kidney disease stage 3 , 2017, Oncotarget.

[13]  G. Russo,et al.  Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes , 2017, Diabetes, obesity & metabolism.

[14]  K. Fukuo,et al.  Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability Is an Independent Determinant of Carotid Intima-Media Thickness in Patients With Type 2 Diabetes , 2017, Journal of clinical medicine research.

[15]  D. Waters,et al.  Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial. , 2017, The American journal of cardiology.

[16]  Mary E. Haas,et al.  The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia , 2016, Circulation.

[17]  N. Vaziri.  Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. , 2016, Kidney international.

[18]  Benjamin Bowe,et al.  Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. , 2016, Kidney international.

[19]  J. Mattana,et al.  Cholesterol Metabolism in CKD. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  C. Alpers,et al.  Foam cells and the pathogenesis of kidney disease , 2015, Current opinion in nephrology and hypertension.

[21]  S. Bangalore,et al.  Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial. , 2015, Journal of the American College of Cardiology.

[22]  J. Goldstein,et al.  A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins , 2015, Cell.

[23]  Mahboob Rahman,et al.  Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[24]  M. Tonelli,et al.  KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. , 2014, Kidney international.

[25]  T. Jørgensen,et al.  Seasonality of cardiovascular risk factors: an analysis including over 230 000 participants in 15 countries , 2014, Heart.

[26]  David C. Wheeler,et al.  KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease Foreword , 2013 .

[27]  N. Kressin,et al.  A pilot study identifying statin nonadherence with visit-to-visit variability of low-density lipoprotein cholesterol. , 2013, The American journal of cardiology.

[28]  C. Schmid,et al.  Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. , 2011, Kidney international.

[29]  G. Sesti,et al.  Endothelial Dysfunction and Subsequent Decline in Glomerular Filtration Rate in Hypertensive Patients , 2010, Circulation.

[30]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[31]  B. Walker,et al.  Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. , 2008, The Journal of endocrinology.

[32]  T. Nickolas,et al.  Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. , 2003, Seminars in nephrology.

[33]  Joshua Miller,et al.  A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. , 2002, Transplantation.

[34]  J. Coresh,et al.  Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. , 2000, Kidney international.

[35]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[36]  Notice , 1932, Journal of the Royal Asiatic Society.

[37]  S. Agrawal,et al.  Dyslipidaemia in nephrotic syndrome: mechanisms and treatment , 2018, Nature Reviews Nephrology.

[38]  Hun‐Sung Kim,et al.  Variability in Total Cholesterol Is Associated With the Risk of End-Stage Renal Disease: A Nationwide Population-Based Study , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[39]  N. Vaziri.  HDL abnormalities in nephrotic syndrome and chronic kidney disease , 2016, Nature Reviews Nephrology.

[40]  R. Garrick.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011 .